

ESTTA Tracking number: **ESTTA1243102**

Filing date: **10/21/2022**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding No.	91274513
Filing Party	Defendant Natera, Inc.
Other Party	Plaintiff Horizon Pharma USA Inc., Horizon Therapeutics Ireland DAC
Pending Motion	There is no motion currently pending and no other motion is being filed concurrent with this consent motion.

Consent Motion to Extend

The Time to Answer is currently set to close on 10/22/2022. Natera, Inc. requests that such date be extended for 60 days, or until 12/21/2022, and that all subsequent dates be reset accordingly.

Time to Answer	12/21/2022
Deadline for Discovery Conference	01/20/2023
Discovery Opens	01/20/2023
Initial Disclosures Due	02/19/2023
Expert Disclosures Due	06/19/2023
Discovery Closes	07/19/2023
Plaintiff's Pretrial Disclosures Due	09/02/2023
Plaintiff's 30-day Trial Period Ends	10/17/2023
Defendant's Pretrial Disclosures Due	11/01/2023
Defendant's 30-day Trial Period Ends	12/16/2023
Plaintiff's Rebuttal Disclosures Due	12/31/2023
Plaintiff's 15-day Rebuttal Period Ends	01/30/2024
Plaintiff's Opening Brief Due	03/30/2024
Defendant's Brief Due	04/29/2024
Plaintiff's Reply Brief Due	05/14/2024
Request for Oral Hearing (optional) Due	05/24/2024

The grounds for this request are as follows:

- *Parties are engaged in settlement discussions*

Natera, Inc. has secured the express consent of all other parties to this proceeding for the extension and re-setting of dates requested herein.

Certificate of Service

The undersigned hereby certifies that a copy of this submission has been served upon all parties, at their address of record by Email on this date.

Respectfully submitted,

/Cassidy J. Grunninger/

Cassidy J. Grunninger/

cgrunninger@foley.com, ipdocketing@foley.com, tschulz@foley.com, jdewitte@foley.com

10/21/2022